Literature DB >> 6341391

Stimulation of renal prostaglandins by pressor hormones in man: comparison of prostaglandin E2 and prostacyclin (6 keto prostaglandin F1 alpha).

J Nadler, R D Zipser, R Coleman, R Horton.   

Abstract

The effect of vasoconstrictive agonists and their nonpressor analogs on renal prostaglandin production was investigated in normal subjects maintained on constant diets. Arginine vasopressin (AVP), 10 U, desamino-d arginine vasopressin (dDAVP), 4 micrograms, angiotensin II (AII), 5 ng/kg . min, des-Asp angiotensin II (AIII), 5 ng/kg . min, norepinephrine (NE), 0.1 microgram/kg . min, and NE plus phenoxybenzamine (PHB), 0.8 mg/kg, were administered on separate days. Prostaglandin E2 (PGE2) and the stable prostacyclin metabolite, 6 keto prostaglandin F1 alpha were measured in 4-h urine collections by procedures with high resolution chromatography and RIA using highly specific antisera. AVP and dDAVP similarly reduced urine volume and increased urine osmolality. AII, AIII, NE, and NE + PHB did not alter basal urine volume, osmolality, creatinine, or electrolyte excretion. Blood pressure was similarly increased by AII and NE infusions (23 +/- 3 vs. 19 +/- 2 (SE) mm Hg). AVP and AII increased only PGE2 excretion (61 +/- 8 to 151 +/- 34 ng/4 h for AVP, and 38.7 +/- 7 to 75 +/- 19 ng/4 h for AII, P less than 0.05). The nonpressor analogs, dDAVP and AIII, had no effect on urinary prostaglandin excretion. In contrast, NE increased both PGE2 (from 38.7 +/- 7 to 74.5 +/- 12 ng/4 h, P less than 0.02) and 6 keto prostaglandin F1 alpha (from 34.6 +/- 8 to 56.1 +/- 9 ng/4 h, P less than 0.02). alpha-Blockade with PHB totally abolished the NE-induced systemic pressor and prostaglandin stimulatory effect. These data suggest that renal PGE2 and prostacyclin are not altered in parallel by vasoactive stimuli. PGE2 appears to be released in response to agents that induce renal vasoconstriction and reduced renal blood flow whereas renal prostacyclin excretion is stimulated by an adrenergic agonist via alpha-receptor activation and not vasoconstriction per se.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6341391     DOI: 10.1210/jcem-56-6-1260

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Biphasic forearm vascular responses to intraarterial arginine vasopressin.

Authors:  S Suzuki; A Takeshita; T Imaizumi; Y Hirooka; M Yoshida; S Ando; M Nakamura
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

2.  Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

Authors:  Youfei Guan; Yahua Zhang; Jing Wu; Zhonghua Qi; Guangrui Yang; Dou Dou; Yuansheng Gao; Lihong Chen; Xiaoyan Zhang; Linda S Davis; Mingfeng Wei; Xuefeng Fan; Monica Carmosino; Chuanming Hao; John D Imig; Richard M Breyer; Matthew D Breyer
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

3.  Fetal and neonatal prostacyclin and thromboxane in relation to mode of delivery.

Authors:  O Ylikorkala; M Pohjavuori; L Rovamo
Journal:  Arch Dis Child       Date:  1986-08       Impact factor: 3.791

4.  Evidence that prostacyclin modulates the vascular actions of calcium in man.

Authors:  J L Nadler; M McKay; V Campese; J Vrbanac; R Horton
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

5.  Evidence against the hypothesis that prostaglandins are the vasodepressor agents of pregnancy. Serial studies in chronically instrumented, conscious rats.

Authors:  K P Conrad; M C Colpoys
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

6.  Renal vasoconstriction by vasopressin V1a receptors is modulated by nitric oxide, prostanoids, and superoxide but not the ADP ribosyl cyclase CD38.

Authors:  Nicholas G Moss; Tayler E Kopple; William J Arendshorst
Journal:  Am J Physiol Renal Physiol       Date:  2014-03-12

7.  Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice.

Authors:  Yuling Chi; Jean-Francois Jasmin; Yoshinori Seki; Michael P Lisanti; Maureen J Charron; David J Lefer; Victor L Schuster
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.